English
简体中文
Total: £ 56.28
Published Date: 2025-09-17 | Pages: 119 | Tables: 126 | Pharma & Healthcare
The global market for Maintenance/Controller Medicines for Asthma and COPD was valued at US$ 6256 million in the year 2024 and is projected to reach a revised size of US$ 8404 million by 2031, growing at a CAGR of 4.2% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Maintenance/Controller Medicines for Asthma and COPD competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Maintenance/controller medicines for asthma and COPD primarily include inhaled corticosteroids (ICS), long-acting β2 agonists (LABA), long-acting muscarinic antagonists (LAMA), and combination therapies. Their development and production heavily rely on upstream suppliers of active pharmaceutical ingredients (APIs) and excipients, with raw materials mainly provided by multinational API manufacturers and specialized chemical producers. Leading pharmaceutical companies such as GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and Novartis hold strong R&D capabilities and significant market share in this sector.
Downstream customers mainly consist of hospitals, specialized clinics, retail pharmacy chains, and chronic disease management institutions, with particularly strong demand in Europe, the U.S., and Asia-Pacific. Given the long-term nature of asthma and COPD, patients have a high dependency on controller medicines, ensuring steady growth within the chronic disease therapeutics market. Looking ahead, innovations in inhalation devices and the adoption of personalized treatment regimens are expected to drive wider adoption of maintenance/controller medicines globally.
In 2024, the global average price of maintenance/controller medicines for asthma and COPD is approximately USD 19.5 per unit, with total sales reaching around 321 million units.
North American market for Maintenance/Controller Medicines for Asthma and COPD is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Maintenance/Controller Medicines for Asthma and COPD is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Maintenance/Controller Medicines for Asthma and COPD include AstraZeneca, Boehringer Ingelheim, The Menarini Group, Alfasigma, Gebro-Pharma, Kohl Medical, LEK-AM, Polpharma, Adamed Group, STADA Arzneimittel, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Maintenance/Controller Medicines for Asthma and COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Maintenance/Controller Medicines for Asthma and COPD.
The Maintenance/Controller Medicines for Asthma and COPD market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Maintenance/Controller Medicines for Asthma and COPD market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Maintenance/Controller Medicines for Asthma and COPD manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AstraZeneca
Boehringer Ingelheim
The Menarini Group
Alfasigma
Gebro-Pharma
Kohl Medical
LEK-AM
Polpharma
Adamed Group
STADA Arzneimittel
GSK
Chiesi Farmaceutici
Teva Pharmaceutical
Sumitomo Pharma
Cipla
Glenmark Pharmaceuticals
Orion Corporation
Bausch Health
Viatris
Novartis
Covis Pharma
Zentiva
Lunan Better Pharmaceutical
Jewim Pharmaceutical
Shanghai Pharmaceuticals
Zhejiang Xianjun Pharmaceutical
Anhui Wellman Pharmaceutical
Chia Tai Tianqing Pharmaceutical Group
Nanchang Helioeast Technology
Segment by Type
Inhaled Corticosteroids (ICS)
Long-Acting Muscarinic Antagonists (LAMA)
Long-Acting Beta2 Agonists (LABA)
LAMA-LABA
ICS-LABA
ICS-LABA-LAMA
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Maintenance/Controller Medicines for Asthma and COPD manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Maintenance/Controller Medicines for Asthma and COPD in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Maintenance/Controller Medicines for Asthma and COPD Market Overview
1.1 Product Definition
1.2 Maintenance/Controller Medicines for Asthma and COPD by Type
1.2.1 Global Maintenance/Controller Medicines for Asthma and COPD Market Value Comparison by Type (2024 VS 2031)
1.2.2 Inhaled Corticosteroids (ICS)
1.2.3 Long-Acting Muscarinic Antagonists (LAMA)
1.2.4 Long-Acting Beta2 Agonists (LABA)
1.2.5 LAMA-LABA
1.2.6 ICS-LABA
1.2.7 ICS-LABA-LAMA
1.3 Maintenance/Controller Medicines for Asthma and COPD by Application
1.3.1 Global Maintenance/Controller Medicines for Asthma and COPD Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Maintenance/Controller Medicines for Asthma and COPD Market Size Estimates and Forecasts
1.4.1 Global Maintenance/Controller Medicines for Asthma and COPD Revenue 2020-2031
1.4.2 Global Maintenance/Controller Medicines for Asthma and COPD Sales 2020-2031
1.4.3 Global Maintenance/Controller Medicines for Asthma and COPD Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Maintenance/Controller Medicines for Asthma and COPD Market Competition by Manufacturers
2.1 Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Manufacturers (2020-2025)
2.2 Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Maintenance/Controller Medicines for Asthma and COPD Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Maintenance/Controller Medicines for Asthma and COPD, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Maintenance/Controller Medicines for Asthma and COPD, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Maintenance/Controller Medicines for Asthma and COPD, Product Type & Application
2.7 Global Key Manufacturers of Maintenance/Controller Medicines for Asthma and COPD, Date of Enter into This Industry
2.8 Global Maintenance/Controller Medicines for Asthma and COPD Market Competitive Situation and Trends
2.8.1 Global Maintenance/Controller Medicines for Asthma and COPD Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Maintenance/Controller Medicines for Asthma and COPD Players Market Share by Revenue
2.8.3 Global Maintenance/Controller Medicines for Asthma and COPD Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Maintenance/Controller Medicines for Asthma and COPD Market Scenario by Region
3.1 Global Maintenance/Controller Medicines for Asthma and COPD Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Maintenance/Controller Medicines for Asthma and COPD Sales by Region: 2020-2031
3.2.1 Global Maintenance/Controller Medicines for Asthma and COPD Sales by Region: 2020-2025
3.2.2 Global Maintenance/Controller Medicines for Asthma and COPD Sales by Region: 2026-2031
3.3 Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Region: 2020-2031
3.3.1 Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Region: 2020-2025
3.3.2 Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Region: 2026-2031
3.4 North America Maintenance/Controller Medicines for Asthma and COPD Market Facts & Figures by Country
3.4.1 North America Maintenance/Controller Medicines for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2020-2031)
3.4.3 North America Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Maintenance/Controller Medicines for Asthma and COPD Market Facts & Figures by Country
3.5.1 Europe Maintenance/Controller Medicines for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2020-2031)
3.5.3 Europe Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Maintenance/Controller Medicines for Asthma and COPD Market Facts & Figures by Region
3.6.1 Asia Pacific Maintenance/Controller Medicines for Asthma and COPD Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Maintenance/Controller Medicines for Asthma and COPD Sales by Region (2020-2031)
3.6.3 Asia Pacific Maintenance/Controller Medicines for Asthma and COPD Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Maintenance/Controller Medicines for Asthma and COPD Market Facts & Figures by Country
3.7.1 Latin America Maintenance/Controller Medicines for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2020-2031)
3.7.3 Latin America Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Maintenance/Controller Medicines for Asthma and COPD Market Facts & Figures by Country
3.8.1 Middle East and Africa Maintenance/Controller Medicines for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2020-2031)
3.8.3 Middle East and Africa Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2020-2031)
4.1.1 Global Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2020-2025)
4.1.2 Global Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2026-2031)
4.1.3 Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Type (2020-2031)
4.2 Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Type (2020-2031)
4.2.1 Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Type (2020-2025)
4.2.2 Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Type (2026-2031)
4.2.3 Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Type (2020-2031)
4.3 Global Maintenance/Controller Medicines for Asthma and COPD Price by Type (2020-2031)
5 Segment by Application
5.1 Global Maintenance/Controller Medicines for Asthma and COPD Sales by Application (2020-2031)
5.1.1 Global Maintenance/Controller Medicines for Asthma and COPD Sales by Application (2020-2025)
5.1.2 Global Maintenance/Controller Medicines for Asthma and COPD Sales by Application (2026-2031)
5.1.3 Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Application (2020-2031)
5.2 Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Application (2020-2031)
5.2.1 Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Application (2020-2025)
5.2.2 Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Application (2026-2031)
5.2.3 Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Application (2020-2031)
5.3 Global Maintenance/Controller Medicines for Asthma and COPD Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AstraZeneca Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Boehringer Ingelheim
6.2.1 Boehringer Ingelheim Company Information
6.2.2 Boehringer Ingelheim Description and Business Overview
6.2.3 Boehringer Ingelheim Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Boehringer Ingelheim Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.2.5 Boehringer Ingelheim Recent Developments/Updates
6.3 The Menarini Group
6.3.1 The Menarini Group Company Information
6.3.2 The Menarini Group Description and Business Overview
6.3.3 The Menarini Group Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.3.4 The Menarini Group Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.3.5 The Menarini Group Recent Developments/Updates
6.4 Alfasigma
6.4.1 Alfasigma Company Information
6.4.2 Alfasigma Description and Business Overview
6.4.3 Alfasigma Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Alfasigma Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.4.5 Alfasigma Recent Developments/Updates
6.5 Gebro-Pharma
6.5.1 Gebro-Pharma Company Information
6.5.2 Gebro-Pharma Description and Business Overview
6.5.3 Gebro-Pharma Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Gebro-Pharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.5.5 Gebro-Pharma Recent Developments/Updates
6.6 Kohl Medical
6.6.1 Kohl Medical Company Information
6.6.2 Kohl Medical Description and Business Overview
6.6.3 Kohl Medical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Kohl Medical Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.6.5 Kohl Medical Recent Developments/Updates
6.7 LEK-AM
6.7.1 LEK-AM Company Information
6.7.2 LEK-AM Description and Business Overview
6.7.3 LEK-AM Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.7.4 LEK-AM Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.7.5 LEK-AM Recent Developments/Updates
6.8 Polpharma
6.8.1 Polpharma Company Information
6.8.2 Polpharma Description and Business Overview
6.8.3 Polpharma Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Polpharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.8.5 Polpharma Recent Developments/Updates
6.9 Adamed Group
6.9.1 Adamed Group Company Information
6.9.2 Adamed Group Description and Business Overview
6.9.3 Adamed Group Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Adamed Group Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.9.5 Adamed Group Recent Developments/Updates
6.10 STADA Arzneimittel
6.10.1 STADA Arzneimittel Company Information
6.10.2 STADA Arzneimittel Description and Business Overview
6.10.3 STADA Arzneimittel Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.10.4 STADA Arzneimittel Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.10.5 STADA Arzneimittel Recent Developments/Updates
6.11 GSK
6.11.1 GSK Company Information
6.11.2 GSK Description and Business Overview
6.11.3 GSK Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.11.4 GSK Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.11.5 GSK Recent Developments/Updates
6.12 Chiesi Farmaceutici
6.12.1 Chiesi Farmaceutici Company Information
6.12.2 Chiesi Farmaceutici Description and Business Overview
6.12.3 Chiesi Farmaceutici Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Chiesi Farmaceutici Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.12.5 Chiesi Farmaceutici Recent Developments/Updates
6.13 Teva Pharmaceutical
6.13.1 Teva Pharmaceutical Company Information
6.13.2 Teva Pharmaceutical Description and Business Overview
6.13.3 Teva Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Teva Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.13.5 Teva Pharmaceutical Recent Developments/Updates
6.14 Sumitomo Pharma
6.14.1 Sumitomo Pharma Company Information
6.14.2 Sumitomo Pharma Description and Business Overview
6.14.3 Sumitomo Pharma Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Sumitomo Pharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.14.5 Sumitomo Pharma Recent Developments/Updates
6.15 Cipla
6.15.1 Cipla Company Information
6.15.2 Cipla Description and Business Overview
6.15.3 Cipla Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Cipla Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.15.5 Cipla Recent Developments/Updates
6.16 Glenmark Pharmaceuticals
6.16.1 Glenmark Pharmaceuticals Company Information
6.16.2 Glenmark Pharmaceuticals Description and Business Overview
6.16.3 Glenmark Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Glenmark Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.16.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.17 Orion Corporation
6.17.1 Orion Corporation Company Information
6.17.2 Orion Corporation Description and Business Overview
6.17.3 Orion Corporation Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Orion Corporation Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.17.5 Orion Corporation Recent Developments/Updates
6.18 Bausch Health
6.18.1 Bausch Health Company Information
6.18.2 Bausch Health Description and Business Overview
6.18.3 Bausch Health Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Bausch Health Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.18.5 Bausch Health Recent Developments/Updates
6.19 Viatris
6.19.1 Viatris Company Information
6.19.2 Viatris Description and Business Overview
6.19.3 Viatris Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Viatris Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.19.5 Viatris Recent Developments/Updates
6.20 Novartis
6.20.1 Novartis Company Information
6.20.2 Novartis Description and Business Overview
6.20.3 Novartis Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Novartis Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.20.5 Novartis Recent Developments/Updates
6.21 Covis Pharma
6.21.1 Covis Pharma Company Information
6.21.2 Covis Pharma Description and Business Overview
6.21.3 Covis Pharma Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Covis Pharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.21.5 Covis Pharma Recent Developments/Updates
6.22 Zentiva
6.22.1 Zentiva Company Information
6.22.2 Zentiva Description and Business Overview
6.22.3 Zentiva Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.22.4 Zentiva Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.22.5 Zentiva Recent Developments/Updates
6.23 Lunan Better Pharmaceutical
6.23.1 Lunan Better Pharmaceutical Company Information
6.23.2 Lunan Better Pharmaceutical Description and Business Overview
6.23.3 Lunan Better Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.23.4 Lunan Better Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.23.5 Lunan Better Pharmaceutical Recent Developments/Updates
6.24 Jewim Pharmaceutical
6.24.1 Jewim Pharmaceutical Company Information
6.24.2 Jewim Pharmaceutical Description and Business Overview
6.24.3 Jewim Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.24.4 Jewim Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.24.5 Jewim Pharmaceutical Recent Developments/Updates
6.25 Shanghai Pharmaceuticals
6.25.1 Shanghai Pharmaceuticals Company Information
6.25.2 Shanghai Pharmaceuticals Description and Business Overview
6.25.3 Shanghai Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.25.4 Shanghai Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.25.5 Shanghai Pharmaceuticals Recent Developments/Updates
6.26 Zhejiang Xianjun Pharmaceutical
6.26.1 Zhejiang Xianjun Pharmaceutical Company Information
6.26.2 Zhejiang Xianjun Pharmaceutical Description and Business Overview
6.26.3 Zhejiang Xianjun Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.26.4 Zhejiang Xianjun Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.26.5 Zhejiang Xianjun Pharmaceutical Recent Developments/Updates
6.27 Anhui Wellman Pharmaceutical
6.27.1 Anhui Wellman Pharmaceutical Company Information
6.27.2 Anhui Wellman Pharmaceutical Description and Business Overview
6.27.3 Anhui Wellman Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.27.4 Anhui Wellman Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.27.5 Anhui Wellman Pharmaceutical Recent Developments/Updates
6.28 Chia Tai Tianqing Pharmaceutical Group
6.28.1 Chia Tai Tianqing Pharmaceutical Group Company Information
6.28.2 Chia Tai Tianqing Pharmaceutical Group Description and Business Overview
6.28.3 Chia Tai Tianqing Pharmaceutical Group Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.28.4 Chia Tai Tianqing Pharmaceutical Group Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.28.5 Chia Tai Tianqing Pharmaceutical Group Recent Developments/Updates
6.29 Nanchang Helioeast Technology
6.29.1 Nanchang Helioeast Technology Company Information
6.29.2 Nanchang Helioeast Technology Description and Business Overview
6.29.3 Nanchang Helioeast Technology Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.29.4 Nanchang Helioeast Technology Maintenance/Controller Medicines for Asthma and COPD Product Portfolio
6.29.5 Nanchang Helioeast Technology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Maintenance/Controller Medicines for Asthma and COPD Industry Chain Analysis
7.2 Maintenance/Controller Medicines for Asthma and COPD Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Maintenance/Controller Medicines for Asthma and COPD Production Mode & Process Analysis
7.4 Maintenance/Controller Medicines for Asthma and COPD Sales and Marketing
7.4.1 Maintenance/Controller Medicines for Asthma and COPD Sales Channels
7.4.2 Maintenance/Controller Medicines for Asthma and COPD Distributors
7.5 Maintenance/Controller Medicines for Asthma and COPD Customer Analysis
8 Maintenance/Controller Medicines for Asthma and COPD Market Dynamics
8.1 Maintenance/Controller Medicines for Asthma and COPD Industry Trends
8.2 Maintenance/Controller Medicines for Asthma and COPD Market Drivers
8.3 Maintenance/Controller Medicines for Asthma and COPD Market Challenges
8.4 Maintenance/Controller Medicines for Asthma and COPD Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Maintenance/Controller Medicines for Asthma and COPD Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Maintenance/Controller Medicines for Asthma and COPD Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Maintenance/Controller Medicines for Asthma and COPD Market Competitive Situation by Manufacturers in 2024
Table 4. Global Maintenance/Controller Medicines for Asthma and COPD Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Maintenance/Controller Medicines for Asthma and COPD Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Maintenance/Controller Medicines for Asthma and COPD Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Maintenance/Controller Medicines for Asthma and COPD, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Maintenance/Controller Medicines for Asthma and COPD, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Maintenance/Controller Medicines for Asthma and COPD, Product Type & Application
Table 12. Global Key Manufacturers of Maintenance/Controller Medicines for Asthma and COPD, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Maintenance/Controller Medicines for Asthma and COPD by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Maintenance/Controller Medicines for Asthma and COPD as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Maintenance/Controller Medicines for Asthma and COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Maintenance/Controller Medicines for Asthma and COPD Sales by Region (2020-2025) & (K Units)
Table 18. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Region (2020-2025)
Table 19. Global Maintenance/Controller Medicines for Asthma and COPD Sales by Region (2026-2031) & (K Units)
Table 20. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Region (2026-2031)
Table 21. Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Region (2020-2025)
Table 23. Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Region (2026-2031)
Table 25. North America Maintenance/Controller Medicines for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 27. North America Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 28. North America Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Maintenance/Controller Medicines for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 32. Europe Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 33. Europe Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Maintenance/Controller Medicines for Asthma and COPD Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Maintenance/Controller Medicines for Asthma and COPD Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Maintenance/Controller Medicines for Asthma and COPD Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Maintenance/Controller Medicines for Asthma and COPD Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Maintenance/Controller Medicines for Asthma and COPD Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Maintenance/Controller Medicines for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Maintenance/Controller Medicines for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Maintenance/Controller Medicines for Asthma and COPD Sales (K Units) by Type (2020-2025)
Table 51. Global Maintenance/Controller Medicines for Asthma and COPD Sales (K Units) by Type (2026-2031)
Table 52. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Type (2020-2025)
Table 53. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Type (2026-2031)
Table 54. Global Maintenance/Controller Medicines for Asthma and COPD Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Maintenance/Controller Medicines for Asthma and COPD Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Type (2020-2025)
Table 57. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Type (2026-2031)
Table 58. Global Maintenance/Controller Medicines for Asthma and COPD Price (US$/Unit) by Type (2020-2025)
Table 59. Global Maintenance/Controller Medicines for Asthma and COPD Price (US$/Unit) by Type (2026-2031)
Table 60. Global Maintenance/Controller Medicines for Asthma and COPD Sales (K Units) by Application (2020-2025)
Table 61. Global Maintenance/Controller Medicines for Asthma and COPD Sales (K Units) by Application (2026-2031)
Table 62. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Application (2020-2025)
Table 63. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Application (2026-2031)
Table 64. Global Maintenance/Controller Medicines for Asthma and COPD Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Maintenance/Controller Medicines for Asthma and COPD Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Application (2020-2025)
Table 67. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Application (2026-2031)
Table 68. Global Maintenance/Controller Medicines for Asthma and COPD Price (US$/Unit) by Application (2020-2025)
Table 69. Global Maintenance/Controller Medicines for Asthma and COPD Price (US$/Unit) by Application (2026-2031)
Table 70. AstraZeneca Company Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. AstraZeneca Maintenance/Controller Medicines for Asthma and COPD Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Boehringer Ingelheim Company Information
Table 76. Boehringer Ingelheim Description and Business Overview
Table 77. Boehringer Ingelheim Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Boehringer Ingelheim Maintenance/Controller Medicines for Asthma and COPD Product
Table 79. Boehringer Ingelheim Recent Developments/Updates
Table 80. The Menarini Group Company Information
Table 81. The Menarini Group Description and Business Overview
Table 82. The Menarini Group Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. The Menarini Group Maintenance/Controller Medicines for Asthma and COPD Product
Table 84. The Menarini Group Recent Developments/Updates
Table 85. Alfasigma Company Information
Table 86. Alfasigma Description and Business Overview
Table 87. Alfasigma Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Alfasigma Maintenance/Controller Medicines for Asthma and COPD Product
Table 89. Alfasigma Recent Developments/Updates
Table 90. Gebro-Pharma Company Information
Table 91. Gebro-Pharma Description and Business Overview
Table 92. Gebro-Pharma Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Gebro-Pharma Maintenance/Controller Medicines for Asthma and COPD Product
Table 94. Gebro-Pharma Recent Developments/Updates
Table 95. Kohl Medical Company Information
Table 96. Kohl Medical Description and Business Overview
Table 97. Kohl Medical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Kohl Medical Maintenance/Controller Medicines for Asthma and COPD Product
Table 99. Kohl Medical Recent Developments/Updates
Table 100. LEK-AM Company Information
Table 101. LEK-AM Description and Business Overview
Table 102. LEK-AM Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. LEK-AM Maintenance/Controller Medicines for Asthma and COPD Product
Table 104. LEK-AM Recent Developments/Updates
Table 105. Polpharma Company Information
Table 106. Polpharma Description and Business Overview
Table 107. Polpharma Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Polpharma Maintenance/Controller Medicines for Asthma and COPD Product
Table 109. Polpharma Recent Developments/Updates
Table 110. Adamed Group Company Information
Table 111. Adamed Group Description and Business Overview
Table 112. Adamed Group Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Adamed Group Maintenance/Controller Medicines for Asthma and COPD Product
Table 114. Adamed Group Recent Developments/Updates
Table 115. STADA Arzneimittel Company Information
Table 116. STADA Arzneimittel Description and Business Overview
Table 117. STADA Arzneimittel Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. STADA Arzneimittel Maintenance/Controller Medicines for Asthma and COPD Product
Table 119. STADA Arzneimittel Recent Developments/Updates
Table 120. GSK Company Information
Table 121. GSK Description and Business Overview
Table 122. GSK Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. GSK Maintenance/Controller Medicines for Asthma and COPD Product
Table 124. GSK Recent Developments/Updates
Table 125. Chiesi Farmaceutici Company Information
Table 126. Chiesi Farmaceutici Description and Business Overview
Table 127. Chiesi Farmaceutici Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Chiesi Farmaceutici Maintenance/Controller Medicines for Asthma and COPD Product
Table 129. Chiesi Farmaceutici Recent Developments/Updates
Table 130. Teva Pharmaceutical Company Information
Table 131. Teva Pharmaceutical Description and Business Overview
Table 132. Teva Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Teva Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product
Table 134. Teva Pharmaceutical Recent Developments/Updates
Table 135. Sumitomo Pharma Company Information
Table 136. Sumitomo Pharma Description and Business Overview
Table 137. Sumitomo Pharma Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Sumitomo Pharma Maintenance/Controller Medicines for Asthma and COPD Product
Table 139. Sumitomo Pharma Recent Developments/Updates
Table 140. Cipla Company Information
Table 141. Cipla Description and Business Overview
Table 142. Cipla Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Cipla Maintenance/Controller Medicines for Asthma and COPD Product
Table 144. Cipla Recent Developments/Updates
Table 145. Glenmark Pharmaceuticals Company Information
Table 146. Glenmark Pharmaceuticals Description and Business Overview
Table 147. Glenmark Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. Glenmark Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Product
Table 149. Glenmark Pharmaceuticals Recent Developments/Updates
Table 150. Orion Corporation Company Information
Table 151. Orion Corporation Description and Business Overview
Table 152. Orion Corporation Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. Orion Corporation Maintenance/Controller Medicines for Asthma and COPD Product
Table 154. Orion Corporation Recent Developments/Updates
Table 155. Bausch Health Company Information
Table 156. Bausch Health Description and Business Overview
Table 157. Bausch Health Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 158. Bausch Health Maintenance/Controller Medicines for Asthma and COPD Product
Table 159. Bausch Health Recent Developments/Updates
Table 160. Viatris Company Information
Table 161. Viatris Description and Business Overview
Table 162. Viatris Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 163. Viatris Maintenance/Controller Medicines for Asthma and COPD Product
Table 164. Viatris Recent Developments/Updates
Table 165. Novartis Company Information
Table 166. Novartis Description and Business Overview
Table 167. Novartis Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 168. Novartis Maintenance/Controller Medicines for Asthma and COPD Product
Table 169. Novartis Recent Developments/Updates
Table 170. Covis Pharma Company Information
Table 171. Covis Pharma Description and Business Overview
Table 172. Covis Pharma Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 173. Covis Pharma Maintenance/Controller Medicines for Asthma and COPD Product
Table 174. Covis Pharma Recent Developments/Updates
Table 175. Zentiva Company Information
Table 176. Zentiva Description and Business Overview
Table 177. Zentiva Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 178. Zentiva Maintenance/Controller Medicines for Asthma and COPD Product
Table 179. Zentiva Recent Developments/Updates
Table 180. Lunan Better Pharmaceutical Company Information
Table 181. Lunan Better Pharmaceutical Description and Business Overview
Table 182. Lunan Better Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 183. Lunan Better Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product
Table 184. Lunan Better Pharmaceutical Recent Developments/Updates
Table 185. Jewim Pharmaceutical Company Information
Table 186. Jewim Pharmaceutical Description and Business Overview
Table 187. Jewim Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 188. Jewim Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product
Table 189. Jewim Pharmaceutical Recent Developments/Updates
Table 190. Shanghai Pharmaceuticals Company Information
Table 191. Shanghai Pharmaceuticals Description and Business Overview
Table 192. Shanghai Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 193. Shanghai Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Product
Table 194. Shanghai Pharmaceuticals Recent Developments/Updates
Table 195. Zhejiang Xianjun Pharmaceutical Company Information
Table 196. Zhejiang Xianjun Pharmaceutical Description and Business Overview
Table 197. Zhejiang Xianjun Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 198. Zhejiang Xianjun Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product
Table 199. Zhejiang Xianjun Pharmaceutical Recent Developments/Updates
Table 200. Anhui Wellman Pharmaceutical Company Information
Table 201. Anhui Wellman Pharmaceutical Description and Business Overview
Table 202. Anhui Wellman Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 203. Anhui Wellman Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product
Table 204. Anhui Wellman Pharmaceutical Recent Developments/Updates
Table 205. Chia Tai Tianqing Pharmaceutical Group Company Information
Table 206. Chia Tai Tianqing Pharmaceutical Group Description and Business Overview
Table 207. Chia Tai Tianqing Pharmaceutical Group Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 208. Chia Tai Tianqing Pharmaceutical Group Maintenance/Controller Medicines for Asthma and COPD Product
Table 209. Chia Tai Tianqing Pharmaceutical Group Recent Developments/Updates
Table 210. Nanchang Helioeast Technology Company Information
Table 211. Nanchang Helioeast Technology Description and Business Overview
Table 212. Nanchang Helioeast Technology Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 213. Nanchang Helioeast Technology Maintenance/Controller Medicines for Asthma and COPD Product
Table 214. Nanchang Helioeast Technology Recent Developments/Updates
Table 215. Key Raw Materials Lists
Table 216. Raw Materials Key Suppliers Lists
Table 217. Maintenance/Controller Medicines for Asthma and COPD Distributors List
Table 218. Maintenance/Controller Medicines for Asthma and COPD Customers List
Table 219. Maintenance/Controller Medicines for Asthma and COPD Market Trends
Table 220. Maintenance/Controller Medicines for Asthma and COPD Market Drivers
Table 221. Maintenance/Controller Medicines for Asthma and COPD Market Challenges
Table 222. Maintenance/Controller Medicines for Asthma and COPD Market Restraints
Table 223. Research Programs/Design for This Report
Table 224. Key Data Information from Secondary Sources
Table 225. Key Data Information from Primary Sources
Table 226. Authors List of This Report
List of Figures
Figure 1. Product Picture of Maintenance/Controller Medicines for Asthma and COPD
Figure 2. Global Maintenance/Controller Medicines for Asthma and COPD Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Maintenance/Controller Medicines for Asthma and COPD Market Share by Type: 2024 & 2031
Figure 4. Inhaled Corticosteroids (ICS) Product Picture
Figure 5. Long-Acting Muscarinic Antagonists (LAMA) Product Picture
Figure 6. Long-Acting Beta2 Agonists (LABA) Product Picture
Figure 7. LAMA-LABA Product Picture
Figure 8. ICS-LABA Product Picture
Figure 9. ICS-LABA-LAMA Product Picture
Figure 10. Global Maintenance/Controller Medicines for Asthma and COPD Market Value by Application (2020-2031) & (US$ Million)
Figure 11. Global Maintenance/Controller Medicines for Asthma and COPD Market Share by Application: 2024 & 2031
Figure 12. Hospital
Figure 13. Clinic
Figure 14. Others
Figure 15. Global Maintenance/Controller Medicines for Asthma and COPD Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Maintenance/Controller Medicines for Asthma and COPD Market Size (2020-2031) & (US$ Million)
Figure 17. Global Maintenance/Controller Medicines for Asthma and COPD Sales (2020-2031) & (K Units)
Figure 18. Global Maintenance/Controller Medicines for Asthma and COPD Average Price (US$/Unit) & (2020-2031)
Figure 19. Maintenance/Controller Medicines for Asthma and COPD Report Years Considered
Figure 20. Maintenance/Controller Medicines for Asthma and COPD Sales Share by Manufacturers in 2024
Figure 21. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Share by Manufacturers in 2024
Figure 22. Global 5 and 10 Largest Maintenance/Controller Medicines for Asthma and COPD Players: Market Share by Revenue in Maintenance/Controller Medicines for Asthma and COPD in 2024
Figure 23. Maintenance/Controller Medicines for Asthma and COPD Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Global Maintenance/Controller Medicines for Asthma and COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 25. North America Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 26. North America Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 27. United States Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 30. Europe Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 31. Germany Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. France Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. U.K. Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Italy Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Russia Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Asia Pacific Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Region (2020-2031)
Figure 37. Asia Pacific Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Region (2020-2031)
Figure 38. China Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Japan Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. South Korea Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. India Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Australia Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. China Taiwan Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Southeast Asia Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Latin America Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 46. Latin America Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 47. Mexico Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Brazil Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Argentina Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Colombia Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Middle East and Africa Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 52. Middle East and Africa Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 53. Turkey Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Saudi Arabia Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. UAE Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Global Sales Market Share of Maintenance/Controller Medicines for Asthma and COPD by Type (2020-2031)
Figure 57. Global Revenue Market Share of Maintenance/Controller Medicines for Asthma and COPD by Type (2020-2031)
Figure 58. Global Maintenance/Controller Medicines for Asthma and COPD Price (US$/Unit) by Type (2020-2031)
Figure 59. Global Sales Market Share of Maintenance/Controller Medicines for Asthma and COPD by Application (2020-2031)
Figure 60. Global Revenue Market Share of Maintenance/Controller Medicines for Asthma and COPD by Application (2020-2031)
Figure 61. Global Maintenance/Controller Medicines for Asthma and COPD Price (US$/Unit) by Application (2020-2031)
Figure 62. Maintenance/Controller Medicines for Asthma and COPD Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
